Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure

被引：0
|
作者：
Painchaud, CA
Ghazzi, MM
Selaru, P
Bichet, DG
Chartier, KK
Udelson, JE
机构：
[1] Parke Davis Pharmaceut Res, Ann Arbor, MI USA
[2] Hosp Sacre Coeur Montreal, Montreal, PQ, Canada
[3] New England Med Ctr, Boston, MA 02111 USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2603
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [1] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, C
    Bichet, D
    Udelson, JE
    Ghazzi, MM
    Selaru, P
    Chartier, K
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [2] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [3] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, M
    Thomas, I
    Ghali, JK
    Selaru, P
    Chanoine, F
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2001, 104 (20) : 2417 - 2423
  • [4] Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise
    Balling, Louise
    Wolsk, Emil
    Hassager, Christian
    Boesgaard, Soren
    Goldsmith, Steven R.
    Gustafsson, Finn
    AMERICAN HEART JOURNAL, 2018, 203 : 101 - 104
  • [5] Novel vasopressin V1A and V2 antagonist (Conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia
    Verbalis, JG
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [6] Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia
    Ghali, JK
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [7] Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia
    Verbalis, JG
    Bisaha, JG
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S27 - S27
  • [8] Conivaptan hydrochloride.: Treatment of heart failure, Treatment of hyponatremia, Vasopressin V1a/V2 antagonist.
    Norman, P
    Leeson, PA
    Rabasseda, X
    Castañer, J
    Castañer, RM
    DRUGS OF THE FUTURE, 2000, 25 (11) : 1121 - 1130
  • [9] Pharmacotherapy for hyponatraemia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally
    Abraham, W
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    Nelson, C
    Bakker-Arkema, RG
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
  • [10] Haemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist, in patients with advanced heart failure
    Udelson, J
    Smith, WB
    Hendrix, G
    Painchaud, C
    Ghazzi, MM
    Thomas, I
    Ghali, J
    Selaru, P
    Pressler, M
    Konstam, M
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
12345